Table 1.
Patient characteristics
| Characteristics | n | % |
|---|---|---|
| Age (years) | ||
| ≤60 | 26 | 54.2 |
| >60 | 22 | 25.8 |
| Sex | ||
| Male | 25 | 52.1 |
| Female | 23 | 47.9 |
| ECOG | ||
| 0 | 33 | 68.7 |
| 1 | 15 | 31.3 |
| Location of primary tumor | ||
| Pancreatic cancer | 36 | 75.0 |
| Biliary tract cancer | 12 | 25.0 |
| Extent of disease | ||
| Locally advanced | 27 | 56.2 |
| Metastatic | 21 | 43.8 |
| Biliary drainage | ||
| Endoscopic drainage | 16 | 33.3 |
| Percutaneous drainage | 4 | 8.3 |
| Line of treatment | ||
| Second line | 36 | 75.0 |
| Third line | 12 | 25.0 |
| Prior first-line chemotherapy | ||
| Gemcitabine | 4 | 8.3 |
| Gemcitabine + oxaliplatin | 28 | 58.4 |
| Gemcitabine + cisplatin | 12 | 25.0 |
| Gemcitabine + nab-paclitaxel | 4 | 8.3 |
| Prior second-line chemotherapy | ||
| S-1 | 2 | 4.2 |
| S-1 + oxaliplatin | 10 | 20.8 |
| Current treatment | ||
| FOLFIRI | 33 | 68.7 |
| Irinotecan monotherapy | 15 | 31.3 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FOLFIRI, a chemotherapy regimen containing folinic acid (FOL), fluorouracil (F), and irinotecan (IRI).